SBWire

Global Markets Direct's, 'Epidermolysis Bullosa - Pipeline Review, H2 2014', provides an overview of the Epidermolysis Bullosa's therapeutic pipeline.

Global Markets Direct's, 'Wockhardt Limited - Product Pipeline Review - 2014', provides an overview of the Wockhardt Limited's pharmaceutical research and development focus.

GBI Research, the leading business intelligence provider, has released its latest research, "Major Depressive Disorder Therapeutics in Major Developed Markets to 2020 - New Launches and Modest Uptake of New Adjunctive Treatments to Offset Patent Expiries", which provides insights into Major Depressive Disorder (MDD) in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of the pipeline, clinical trial failure rate and deal analysis for MDD. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research's team of industry experts. In 2013, the value of the MDD therapeutics market in major developed countries amounted to an estimated $8.7 billion. The market is forecast to decline at a negative Compound Annual Growth Rate (CAGR) of 1.1% between 2013 and 2020 to reach $8.1 billion. The decline is due to key patent expiries of blockbuster drugs such as Lexapro, Cymbalta, Abilify, and Seroquel XR during the forecast period. The expected launch of few promising pipeline molecules such as brexpiprazole, cariprazine, ALKS-5461, GLYX-13 is likely to offset the key patent expiries. Recently launched Brintellix which has a novel multimodal mechanism of action and is the only drug which can provide improvements in cognitive function is expected to lead the market by the end of forecasting period.

Global Markets Direct's, 'Neuropathic Pain - Pipeline Review, H2 2014', provides an overview of the Neuropathic Pain's therapeutic pipeline.

Global Markets Direct's, 'Smoking Cessation - Pipeline Review, H2 2014', provides an overview of the Smoking Cessation's therapeutic pipeline.

Huntington's disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. People with Huntington's disease often develop chorea that causes involuntary muscle movements of hands, face, trunk, and feet. The behavioural disorders associated with the disease include depression, psychosis, and changes in personality. Other symptoms of the disease include speech impairment, anxiety, stress, and difficulty in swallowing. People suffering from Huntington's disease usually develop symptoms in their mid-30s and 40s. However, in few cases, disease symptoms appear in childhood or teens. The former case represents the adult-onset form of the disease, while the latter is the early-onset form. The early-onset form is associated with symptoms such as tremors, slow movements, and rigidity. Children with early-onset disease rarely live to adulthood. Currently, there is no approved treatment for Huntington's disease.

Global Markets Direct's, 'ImmunoBiology Ltd. - Product Pipeline Review - 2014', provides an overview of the ImmunoBiology Ltd.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Quark Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Quark Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Trevena, Inc. - Product Pipeline Review - 2014', provides an overview of the Trevena, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'MSM Protein Technologies, Inc. - Product Pipeline Review - 2014', provides an overview of the MSM Protein Technologies, Inc.'s pharmaceutical research and development focus.

GlobalData's clinical trial report, "Hashimoto's Thyroiditis Global Clinical Trials Review, H2, 2014" provides data on the Hashimoto's Thyroiditis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hashimoto's Thyroiditis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hashimoto's Thyroiditis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

As the oncology drug market continues to face significant road bumps in terms of development costs and pricing requirements, the role of Medical Affairs teams working with oncologists becomes ever more critical.

Global Markets Direct's, 'T-Cell Lymphomas - Pipeline Review, H2 2014', provides an overview of the T-Cell Lymphomas's therapeutic pipeline.

Global Markets Direct's, 'Pieris AG - Product Pipeline Review - 2014', provides an overview of the Pieris AG's pharmaceutical research and development focus.

Global Markets Direct's, 'Cancer Pain - Pipeline Review, H2 2014', provides an overview of the Cancer Pain's therapeutic pipeline.

Global Markets Direct's, 'Pruritus - Pipeline Review, H2 2014', provides an overview of the Pruritus's therapeutic pipeline.

Over 500,000 Unique Site Visits reached by pharmaceuticalintelligence.com Reported today by Leaders in Pharmaceutical Business Intelligence (LBPI)

Global Markets Direct's, 'JCR Pharmaceuticals Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the JCR Pharmaceuticals Co., Ltd.'s pharmaceutical research and development focus.

ADHD is a psychiatric disorder, which is mostly found in children. However, adults have also been reported to be diagnosed with ADHD. The patients with ADHD suffer from several problems including hyperactivity, impulsiveness, and lack of focus and concentration. The causes of ADHD are not known. It is believed to be linked with genetic and environmental causes. However, it has been reported to be related with the decrease in the extraneuronal levels of norepinephrine and dopamine. In addition, the patients have an abnormality in the brain structure. It is more prevalent in boys than girls. The management of ADHD is done by counseling, medications, and lifestyle changes.

Global Markets Direct's, 'Biological E. Limited - Product Pipeline Review - 2014', provides an overview of the Biological E. Limited's pharmaceutical research and development focus.

Global Markets Direct's, 'Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2014', provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD)'s therapeutic pipeline.

Global Markets Direct's, 'DiscoveryBiomed, Inc. - Product Pipeline Review - 2014', provides an overview of the DiscoveryBiomed, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Hormone-Sensitive Prostate Cancer - Pipeline Review, H2 2014', provides an overview of the Hormone-Sensitive Prostate Cancer's therapeutic pipeline.

GlobalData has released its new PharmaPoint Drug Evaluation report, "Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023". HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third, and fourth-line metastatic.

Music publishing involves promoting music from sources including independent musicians as well as music publishing houses. Music publishing owns and copyrights compositions from different sources and earns revenue from their sales globally through recordings, public performances, films, and advertisements.